A Phase 2 interventional study of RG1507 in Sarcoma, sponsored by Hoffmann-La Roche. Terminated at 41 sites in 11 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-02-03.
Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 958 studies in Sarcoma with a site in United States — 153 open to participants now, 244 under way, 4 of them phase 3. Sarcoma · United States.
Among the 958 studies in Sarcoma with a site in United States, this one is the 35th largest by enrollment of the 800 interventional ones that give a count, is one of 32 that started in 2007, is one of 310 in phase 2, and was the 282nd registered.
1,609 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →153 of the 958 studies in Sarcoma with a site in United States are open now. Recruiting first, the newest first:
University of Colorado, Denver · Sites in United States
Ages 65–100
M.D. Anderson Cancer Center · Sites in United States
Ages 18–39
Iovance Biotherapeutics, Inc. · Sites in United States
Ages 16–70
St. Jude Children's Research Hospital · Sites in United States
City of Hope Medical Center · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.
This study: 2 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
958 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 393 · Phase 2 426 · Phase 3 42 · Phase 4 4
First in 1983; this study’s year is marked. 32 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 317 is above the median of 41 across 1,254 interventional studies indexed under Sarcoma.
Median enrollment 35 across the 800 interventional studies, 101 across the 100 observational. Of the 650 that completed or were terminated, 245 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
231 of 958 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 8 studies filed under Sarcoma — fewer than ten, so there is no comparison to draw.
78 of the studies in Sarcoma with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01223248Phase 3Memorial Sloan Kettering Cancer CenterRandomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy | 2027-10 |
| NCT02307630Memorial Sloan Kettering Cancer CenterPET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | 2026-11 |
| NCT05099666Massachusetts General HospitalLurbinectedin + Doxorubicin In Leiomyosarcoma | 2026-12 |
| NCT03114527Fox Chase Cancer CenterPhase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS) | 2026-12 |
| NCT00582647Memorial Sloan Kettering Cancer CenterCollection of Tissue & Blood From Patients w/ Benign & Malignant Tumors of the Soft Tissue & Gastrointestinal Tract | 2026-12 |
Add all 78 to your calendar (.ics) → With an account.
Among the 958 studies in Sarcoma with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study was primarily designed to determine objective response, progression-free survival (PFS), and the safety and tolerability of R1507 in participants with recurrent or refractory Ewing's sarcoma, osteosarcoma, synovial sarcoma, rhabdomyosarcoma and other sarcomas including alveolar soft part sarcoma, desmoplastic small round cell tumor, extraskeletal myxoid chondrosarcoma, clear cell sarcoma, and myxoid liposarcoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 1 includes individuals with Ewing's sarcoma who have relapsed within 24 weeks after diagnosis and have received two or more prior chemotherapy regimens.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 2 includes individuals with Ewing's sarcoma who have relapsed more than 24 weeks after diagnosis and have only received one prior chemotherapy regimen.
Drug: RG1507
Participants 2 to 21 years of age with recurrent or refractory sarcoma receive R1507 as 27 mg/kg via IV infusion every 3 weeks until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 3 includes individuals with Ewing's sarcoma who were enrolled and treated following safety evaluation in other cohorts.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 4 includes individuals with osteosarcoma.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 5 includes individuals with synovial sarcoma.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 6 includes individuals with rhabdomyosarcoma.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7a includes individuals with alveolar soft part sarcoma.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7b includes individuals with desmoplastic small round cell tumors.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7c includes individuals with extraskeletal myxoid chondrosarcoma.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7d includes individuals with clear cell sarcoma.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 7e includes individuals with myxoid liposarcoma.
Drug: RG1507
Participants 2 years of age and older with recurrent or refractory sarcoma receive R1507 as 9 mg/kg via IV infusion once weekly until disease progression, intercurrent illness, unacceptable toxicity, prolonged (2-week) time off treatment, withdrawal, loss to follow-up, investigator decision, or death. Cohort 8 includes individuals with subtypes of sarcoma not specified in the protocol.
Drug: RG1507
Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8
Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.
Time frame: Baseline up to 6 years (assessed at baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression)
Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1
The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response) at 18 weeks from start of treatment.
Time frame: Baseline up to 18 weeks (assessed at baseline, every 6 weeks until disease progression)
Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2
Time frame: Baseline up to 6 years
Percentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 1
Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.
Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
PFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 8
The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response at 18 weeks) from start of treatment.
Time frame: Baseline, every 6 weeks until disease progression (up to 18 weeks)
Percentage of Participants With AEs in Cohorts 3-8
Time frame: Baseline up to 6 years
Duration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 8
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.
Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
Time to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 8
TTP is defined as the time from date of randomization until objective tumor progression. According to the WHO Response Criteria, objective tumor progression is \> 25% increase in the area of one or more measurable lesions or the appearance of new lesions.
Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
Failure-Free Survival (FFS) According to WHO Response Criteria in Cohorts 1 to 8
FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause.
Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
Overall Survival (OS) in Cohorts 1 to 8
OS was measured from the time of study registration to the date of death or was censored at the date of last contact.
Time frame: Baseline until death (up to 6 years)
PFS According to WHO Response Criteria in Cohorts 1 to 8
PFS is defined as the duration of time from start of treatment to time of objective progression or death.
Time frame: Baseline, every 6 weeks for 24 weeks, then every 12 weeks until disease progression (up to 6 years)
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) of R1507
Time frame: Predose (0 hours [h]), end of 60-90 minutes infusion (EOI), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)
Pharmacokinetics: Clearance (CL) of R1507
Time frame: Predose (0 h), EOI (infusion over 60-90 minutes), postdose (2, 24, 72-96 h) in Week 1; predose (0 h) and EOI in Weeks 2, 4, 6, 9; predose (0 h), EOI, postdose (48 h) in Week 12; predose (0 h) in Week 13, at final visit (up to 6 years)
A screening period was included prior to administration of study drug. Tumor scans/X-rays were to be obtained within 4 weeks, fluro-D-glucose positron emission tomography (FDG-PET) scans within 2 weeks, and Baseline laboratory evaluations within 1 week before first dose.
| Milestone | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 70 | 54 | 7 | 40 | 25 | 41 | 23 | 14 | 11 | 9 | 12 | 11 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 70 | 54 | 7 | 40 | 25 | 41 | 23 | 14 | 11 | 9 | 12 | 11 |
| Withdrew: Physician decision | 3 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 1 |
| Withdrew: Death | 4 | 0 | 1 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Study closed by sponsor | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 2 | 0 | 0 | 2 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Disease progression | 60 | 50 | 5 | 36 | 23 | 39 | 18 | 12 | 10 | 7 | 12 | 7 |
Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.
| Percentage of Participants | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With Complete or Partial Response, According to World Health Organization (WHO) Criteria in Cohorts 2 to 8 | 11.11 | — | 2.5 | 4.0 | 4.88 | 0 | 0 | 0 | 0 | 0 | 0 |
The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response) at 18 weeks from start of treatment.
| Percentage of Participants | Cohort 1: Ewings Sarcoma Primary Cohort |
|---|---|
| Progression-Free Survival (PFS) Rate According to WHO Response Criteria at 18 Weeks From Start of R2607 Treatment in Cohort 1 | 15.81 |
| percentage of participants | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) in Cohort 1 and 2 | 96 | 96 |
Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.
| percentage of participants | Cohort 1: Ewings Sarcoma Primary Cohort |
|---|---|
| Percentage of Participants With Complete or Partial Response According to WHO Response Criteria in Cohort 1 | 8.57 |
The PFS survival rate is a landmark analysis of progression-free survival at 18 weeks from start of treatment. Progression-free survival rate at 18 weeks is a dichotomous endpoint, with a patient categorized as alive (with either stable disease or objective response at 18 weeks) from start of treatment.
| Percentage of Participants | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS Rate According to WHO Response Criteria at 18 Weeks From Start of R1507 Treatment in Cohorts 2 to 8 | 17.16 | — | 19.69 | 4.00 | 7.32 | 45.40 | 8.16 | 62.34 | 0 | 8.33 | 22.86 |
| percentage of participants | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|
| Percentage of Participants With AEs in Cohorts 3-8 | 85.7 | 100 | 100 | 95 | 91 | 86 | 100 | 100 | 100 | 100 |
The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented. Complete response is the disappearance of all known disease, determined by two consecutive observations not less than 4 weeks apart. Partial response is \>=50% decrease in the total tumor load of the lesions that have been measured to determine the effect of therapy not less than four weeks apart. The observations must be consecutive.
| weeks | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Duration of Response (DOR) According to WHO Response Criteria in Cohorts 1 to 8 | 44.29 (18 to NA) | 42.86 (18.14 to NA) | — | NA (30.14 to NA) | 13.14 (13.14 to NA) | NA (21 to NA) | — | — | — | — | — | — |
TTP is defined as the time from date of randomization until objective tumor progression. According to the WHO Response Criteria, objective tumor progression is \> 25% increase in the area of one or more measurable lesions or the appearance of new lesions.
| weeks | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time to Progression (TTP) According to WHO Response Criteria in Cohorts 1 to 8 | 6.00 (5.29 to 9.71) | 6.00 (5.71 to 8.14) | — | 5.71 (5.57 to 7.00) | 6.00 (5.57 to 6.43) | 5.50 (5.14 to 6.14) | 11.14 (6.00 to 17.71) | 6.14 (5.86 to 11.14) | 18.00 (5.71 to NA) | 5.57 (5.14 to 5.86) | 5.86 (5.29 to 8.43) | 6.14 (5.86 to 10.00) |
FFS was measured from the date of treatment start to the date of documented disease progression, relapse, or death from any cause.
No measurements were reported for this outcome.
OS was measured from the time of study registration to the date of death or was censored at the date of last contact.
| weeks | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Survival (OS) in Cohorts 1 to 8 | 29.57 (20.57 to 37.57) | 43.57 (33.29 to 69.00) | — | 37.14 (25.57 to NA) | 40.71 (21.71 to 64.14) | 30.86 (21.57 to 50.00) | 42.43 (42.43 to NA) | 40.86 (23.57 to NA) | NA (NA to NA) | 17.00 (9.14 to NA) | 36.00 (33.14 to NA) | 17.43 (13.00 to 30.14) |
PFS is defined as the duration of time from start of treatment to time of objective progression or death.
| weeks | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PFS According to WHO Response Criteria in Cohorts 1 to 8 | 6.00 (5.29 to 9.57) | 6.00 (5.71 to 8.14) | — | 5.71 (5.57 to 6.43) | 6.00 (5.43 to 6.14) | 5.43 (5.14 to 6.14) | 11.14 (5.71 to 11.71) | 6.14 (5.86 to 11.14) | 18.00 (5.71 to NA) | 5.57 (5.14 to 5.86) | 5.86 (5.29 to 8.43) | 6.14 (5.86 to 10) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Collected over Baseline up to 6 years. Non-serious events are listed at a 0.05% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Ewings Sarcoma Primary Cohort | 9/70 (12.9%) | 11/70 (15.7%) | 67/70 (95.7%) |
| Cohort 2: Ewings Sarcoma Secondary Cohort | 5/54 (9.3%) | 13/54 (24.1%) | 52/54 (96.3%) |
| Cohort 3: Ewings Sarcoma Expanded Cohort | 2/7 (28.6%) | 1/7 (14.3%) | 6/7 (85.7%) |
| Cohort 4: Osteosarcoma | 7/40 (17.5%) | 4/40 (10%) | 40/40 (100%) |
| Cohort 5: Synovial Sarcoma | 3/25 (12%) | 5/25 (20%) | 25/25 (100%) |
| Cohort 6: Rhabdomyosarcoma | 3/41 (7.3%) | 4/41 (9.8%) | 39/41 (95.1%) |
| Cohort 7a: Alveolar Soft Part Sarcoma | 1/23 (4.3%) | 1/23 (4.3%) | 21/23 (91.3%) |
| Cohort 7b: Desmoplastic Small Round Cell Tumors | 0/14 (0%) | 1/14 (7.1%) | 12/14 (85.7%) |
| Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | 0/11 (0%) | 0/11 (0%) | 11/11 (100%) |
| Cohort 7d: Clear Cell Sarcoma | 1/9 (11.1%) | 3/9 (33.3%) | 9/9 (100%) |
| Cohort 7e: Myxoid Liposarcoma | 1/12 (8.3%) | 2/12 (16.7%) | 12/12 (100%) |
| Cohort 8: Diagnosis Not Specified | 2/11 (18.2%) | 4/11 (36.4%) | 11/11 (100%) |
| Event | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/70 | 0/54 | 1/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 0/9 | 0/12 | 0/11 |
| PyrexiaGeneral disorders | 0/70 | 0/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 1/9 | 0/12 | 0/11 |
| Intestinal perforationGastrointestinal disorders | 0/70 | 0/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 1/9 | 0/12 | 0/11 |
| VomitingGastrointestinal disorders | 0/70 | 1/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 1/9 | 0/12 | 0/11 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 0/70 | 0/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 0/9 | 0/12 | 1/11 |
| ConstipationGastrointestinal disorders | 0/70 | 1/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 0/9 | 0/12 | 1/11 |
| Neck painMusculoskeletal and connective tissue disorders | 0/70 | 0/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 0/9 | 0/12 | 1/11 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/70 | 0/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 0/9 | 0/12 | 1/11 |
| Escherichia sepsisInfections and infestations | 0/70 | 0/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 0/9 | 1/12 | 0/11 |
| Staphylococcal infectionInfections and infestations | 0/70 | 0/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 0/9 | 1/12 | 0/11 |
| Event | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 19/70 | 22/54 | 1/7 | 13/40 | 3/25 | 14/41 | 5/23 | 5/14 | 5/11 | 5/9 | 5/12 | 3/11 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/70 | 10/54 | 0/7 | 9/40 | 5/25 | 3/41 | 6/23 | 0/14 | 6/11 | 3/9 | 1/12 | 1/11 |
| HyperglycaemiaMetabolism and nutrition disorders | 12/70 | 9/54 | 0/7 | 5/40 | 4/25 | 4/41 | 4/23 | 3/14 | 5/11 | 2/9 | 0/12 | 0/11 |
| NauseaGastrointestinal disorders | 9/70 | 20/54 | 0/7 | 7/40 | 5/25 | 10/41 | 6/23 | 1/14 | 2/11 | 4/9 | 3/12 | 3/11 |
| HeadacheNervous system disorders | 10/70 | 17/54 | 0/7 | 4/40 | 0/25 | 7/41 | 5/23 | 3/14 | 1/11 | 1/9 | 1/12 | 4/11 |
| AstheniaGeneral disorders | 5/70 | 9/54 | 0/7 | 4/40 | 0/25 | 2/41 | 2/23 | 0/14 | 0/11 | 1/9 | 0/12 | 4/11 |
| ConstipationGastrointestinal disorders | 12/70 | 10/54 | 0/7 | 7/40 | 2/25 | 3/41 | 3/23 | 3/14 | 3/11 | 3/9 | 2/12 | 1/11 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 5/70 | 5/54 | 0/7 | 5/40 | 1/25 | 0/41 | 1/23 | 1/14 | 1/11 | 3/9 | 1/12 | 2/11 |
| HaemoglobinInvestigations | 1/70 | 1/54 | 0/7 | 0/40 | 0/25 | 0/41 | 0/23 | 0/14 | 0/11 | 3/9 | 0/12 | 0/11 |
| DiarrhoeaGastrointestinal disorders | 11/70 | 15/54 | 0/7 | 8/40 | 3/25 | 6/41 | 7/23 | 1/14 | 3/11 | 0/9 | 2/12 | 0/11 |
| Age, Continuous(Years) | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 27 ± 10.72 | 28.3 ± 12.9 | 13.3 ± 3.15 | 33.8 ± 18.83 | 41.7 ± 16.11 | 26.5 ± 12.21 | 31.7 ± 13.67 | 23.1 ± 6.09 | 60.9 ± 11.27 | 26.9 ± 11.01 | 50.6 ± 11.06 | 30.7 ± 18.56 | 31.2 ± 13.36 |
| Sex: Female, Male(Participants) | Cohort 1: Ewings Sarcoma Primary Cohort | Cohort 2: Ewings Sarcoma Secondary Cohort | Cohort 3: Ewings Sarcoma Expanded Cohort | Cohort 4: Osteosarcoma | Cohort 5: Synovial Sarcoma | Cohort 6: Rhabdomyosarcoma | Cohort 7a: Alveolar Soft Part Sarcoma | Cohort 7b: Desmoplastic Small Round Cell Tumors. | Cohort 7c: Extraskeletal Myxoid Chondrosarcoma | Cohort 7d: Clear Cell Sarcoma | Cohort 7e: Myxoid Liposarcoma | Cohort 8: Diagnosis Not Specified | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 20 | 22 | 3 | 20 | 11 | 18 | 12 | 1 | 3 | 2 | 3 | 3 | 118 |
| Male | 50 | 32 | 4 | 20 | 14 | 23 | 11 | 13 | 8 | 7 | 9 | 8 | 199 |
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/members/ourmembers/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Dec 2007 to primary completion in Feb 2014, 74 months.
Results were first posted in Feb 2021, 6 years 11 months after primary completion. A results delay was requested in Nov 2016.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Teprotumumab